MarketMoodz
Novartis to pay up to $2B for Excellergy in bolt-on bid
Novartis is reportedly buying Excellergy for up to $2 billion, including upfront payments and milestones, with closing expected in the first half of 2026 subject to regulatory approvals. The Palo Alto biotech’s lead asset, Exl-111, would widen Novartis’ immunology portfolio as patent cliffs loom on top-selling drugs.
Key Takeaways
- Novartis to acquire Excellergy for up to $2B, with upfront and milestone payments and a target close in H1 2026 subject to approvals.
- Excellergy is privately held; its lead asset Exl-111 is an early-stage immunology/allergy candidate.
- This deal follows other mega-bio deals this week, including Pikavation Therapeutics (Synnovation) for up to $3B.
- The move aims to offset patent expirations on Entresto and Cosentyx by strengthening the immunology portfolio.
- Analysts say bolt-on mid-stage deals target validated biology but carry uncertainty and integration risk.
People Involved
- Vas Narasimhan CEO, Novartis
- Mukul Mehta CFO, Novartis
- Chris Sheldon Novartis Executive
Entities Involved
- Novartis AG (NVS) Buyer / pharmaceutical company
- Excellergy Privately held Palo Alto biotech
- Exl-111 Lead asset of Excellergy
- Pikavation Therapeutics Biotech; part of Synnovation deal
- Synnovation Acquirer of Pikavation Therapeutics
- Avidity Biosciences Earlier acquisition by Novartis (Feb) adding neuromuscular programs
- Merck & Co. (MRK) Part of week’s mega-deal landscape
- Terns Pharmaceuticals Target of Merck’s deal
- GSK Active in bolt-on deals
- AstraZeneca Active in bolt-on deals
MarketMoodz Analysis
Novartis’s bid for Excellergy underscores a continued shift in big pharma toward bolt-on acquisitions to accelerate growth and fill late-stage gaps as patent cliffs bite Entresto and Cosentyx. If Exl-111 progresses through development, the drug could contribute near- to mid-term value and diversify the immunology portfolio beyond the core brands.
Historically, bolt-on deals in mid-stage programs can deliver meaningful pipeline optionality but hinge on successful development and seamless integration. The week’s flurry of multi-billion-dollar biotech deals signals strong sponsor appetite and the importance for investors to monitor regulatory timing, deal financing, and potential earnings impact from accretion or costs. Watch for updates on Excellergy’s development milestones and how the Pikavation/Synnovation agreement proceeds, as well as any commentary on how these actions affect Novartis’s broader strategy.
Source: Original Article
Get AI-Powered Market Insights
Stay ahead of market-moving events with our real-time analysis and stock ratings.
Start Your Free Trial